NextCure (FRA:2US) Dividends per Share : €0.00 (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Dividends per Share?

NextCure's dividends per share for the three months ended in Dec. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, NextCure's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

NextCure Dividends per Share Historical Data

The historical data trend for NextCure's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Dividends per Share Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

NextCure Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of NextCure's Dividends per Share

For the Biotechnology subindustry, NextCure's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCure's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NextCure's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

NextCure Dividends per Share Calculation

Dividends paid to per common share.

NextCure (FRA:2US) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

NextCure's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.392
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

NextCure Dividends per Share Related Terms

Thank you for viewing the detailed overview of NextCure's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Headlines

No Headlines